Business Context and Reporting Period
Company: China SXT Pharmaceuticals, Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended September 30, 2025
Filing Date: December 31, 2025
Principal Executive Office: 178 Taidong Rd North, Taizhou Jiangsu, China
This filing furnishes the Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the specified period. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text contains the cover page and exhibit list for the Form 6-K but does not include the actual financial data tables or the MD&A content.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Note: Specific numerical values for financial performance are absent from the source text provided.
Material Changes
The filing text does not contain the comparative analysis or specific details regarding material changes versus the prior comparable period (six months ended September 30, 2024). This information is referenced as being contained in Exhibit 99.1 and Exhibit 99.2, which are not included in the input text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, contingencies, or details on unusual items. These disclosures are expected to be found in the attached "Management's Discussion and Analysis of Financial Condition and Results of Operations" (Exhibit 99.1), the content of which is not present in the source data.
Investor Verification Checklist
- Verify the actual revenue and net income figures in the attached Unaudited Condensed Consolidated Financial Statements (Exhibit 99.2).
- Review the Management's Discussion and Analysis (Exhibit 99.1) for specific drivers of performance and year-over-year comparisons.
- Confirm the status of liquidity and debt obligations as detailed in the full financial statements.
- Check for any new risk factors or regulatory updates specific to the Chinese pharmaceutical sector mentioned in the full MD&A.